Biogen (BIIB) : 10 brokerage houses believe that Biogen (BIIB) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 6 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Biogen (BIIB). Zacks Investment Research suggests a Buy with a rank of 2.The median of all the 17 Wall Street Analysts endorse the stock as a Buy with a rating of 1.74.
Biogen (BIIB) : The most positive equity analysts on Biogen (BIIB) expects the shares to touch $414, whereas, the least positive believes that the stock will trade at $268 in the short term. The company is covered by 14 Wall Street Brokerage Firms. The average price target for shares are $347.86 with an expected fluctuation of $45.98 from the mean.
For the current week, the company shares have a recommendation consensus of Buy. Also, Equity Analysts at the Brokerage Firm, Morgan Stanley, maintains their rating on the shares of Biogen (NASDAQ:BIIB). Morgan Stanley has a Overweight rating on the shares. As per the latest research report, the brokerage house raises the price target to $385 per share from a prior target of $383. The rating by the firm was issued on July 21, 2016.
Biogen (NASDAQ:BIIB): The stock opened at $321.77 on Wednesday but the bulls could not build on the opening and the stock topped out at $324.30 for the day. The stock traded down to $310.06 during the day, due to lack of any buying support eventually closed down at $321.34 with a loss of -2.66% for the day. The stock had closed at $330.11 on the previous day. The total traded volume was 6,039,179 shares.
Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Companys marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkins lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.